Brief: BriaCell Partners With Waisman Biomanufacturing To Manufacture And Supply Prostate Cancer Immunotherapy
05/07/2022 14:05
July 5 (Reuters) - BriaCell Therapeutics Corp BCT.TO :
* BRIACELL PARTNERS WITH WAISMAN BIOMANUFACTURING TO
MANUFACTURE
AND SUPPLY PROSTATE CANCER IMMUNOTHERAPY
* BRIACELL - UNDER THE TERMS, WAISMAN WILL BE RESPONSIBLE
FOR
MANUFACTURING PRACTICE MANUFACTURING OF BRIA-PROS™ FOR
ANTICIPATED USE IN CLINICAL STUDIES
Source text for Eikon: ID:nGNX5698GQ
Further company coverage: BCT.TO
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study